Back to Search
Start Over
Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application.
- Source :
-
Drug Delivery . Dec2023, Vol. 30 Issue 1, p1-10. 10p. - Publication Year :
- 2023
-
Abstract
- Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfully developed for oral AmB administration, currently undergoing phase I clinical trials. Encouragingly, lipid-AmB conjugates with emulsions also exhibit a better bioavailability, which may be another strategy to design oral AmB formulation in clinical practice. Thus, this review mainly focused on the two lipid-based formulations in clinical trials, and discussed the potential perspectives of AmB-lipid conjugation-loaded nanocochleates and emulsions. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10717544
- Volume :
- 30
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Drug Delivery
- Publication Type :
- Academic Journal
- Accession number :
- 174236354
- Full Text :
- https://doi.org/10.1080/10717544.2022.2161671